biotech / news / / FinanzNachrichten
Cellular Intelligence has secured global rights to Novo Nordisk's Parkinson's program.
Cellular Intelligence has acquired global rights to Novo Nordisk's clinical-stage Parkinson's cell therapy.
KEY POINTS
- Cellular Intelligence will use its AI-native foundation model to accelerate development and lower manufacturing costs.
- Novo Nordisk will become an equity investor in Cellular Intelligence and retain future milestone and royalty options.
- The cell therapy is an allogeneic pluripotent stem cell-derived product currently in a Phase 1/2 trial with FDA Fast Track status.
- Data from the program will further train Cellular Intelligence's AI model for broader cell therapy and regenerative medicine applications.
COMPANIES
Summarized by Newsio from FinanzNachrichten. How we summarize →